정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2109 | Completed | Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia | Coronavirus Infections | Drug: Bevacizumab Injection | Phase 2 | Qilu Hospital of Shandong University, Renmin Hospital of Wuhan University, Moriggia-Pelascini Gravedona Hospital | OTHER | 27 | All | 18 Years ~ 80 Years | Renmin Hospital of Wuhan University, Wuhan, Hubei, China Qilu Hospital of Shandong University, Jinan, Shandong, China Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy |
2108 | Recruiting | Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT | COVID-19 Pneumonia | Drug: Bevacizumab | Not Applicable | Qilu Hospital of Shandong University, Renmin Hospital of Wuhan University, Ialy Moriggia Pelascini Gravedona Hospital S.p.A, Wuhan University, Jiangbei Union Hospital of Huazhong University of science and technology, Shandong Provincial Chest Hospital | OTHER | 140 | All | 18 Years ~ 80 Years | Qilu Hospital of Shandong University, Jinan, Shandong, China |
2107 | Withdrawn | Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection | COVID-19 | Drug: Bicalutamide 150 Mg Oral Tablet Drug: Placebo |
Phase 3 | University of Florida | OTHER | 0 | Male | 18 Years ~ 99 Years | |
2106 | Recruiting | BIO 300 Oral Suspension in Discharged COVID-19 Patients | Pulmonary Fibrosis | Drug: BIO 300 Oral Suspension Drug: Placebo |
Phase 2 | Humanetics Corporation, NYU Langone Health, National Institute of Allergy and Infectious Diseases (NIAID) | INDUSTRY | 66 | All | 18 Years | University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States NYU Langone Health, New York, New York, United States Houston Methodist Research Institute, Houston, Texas, United States |
2105 | Completed | Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions | Bioequivalence | Drug: FAVICOVIR 200 mg Film Tablet Drug: AVIGAN 200 mg Film Tablets |
Phase 1 | Atabay Kimya Sanayi Ticaret A.S., Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti | INDUSTRY | 30 | Male | 20 Years ~ 40 Years | Novagenix Drug R&D Center, Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey |
2104 | Completed | Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions | Bioequivalence | Drug: FAVIRA 200 MG Film Tablet Drug: AVIGAN 200 MG Film Tablets |
Phase 1 | Novelfarma Ilac San. ve Tic. Ltd. Sti., Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti | INDUSTRY | 30 | Male | 20 Years ~ 40 Years | Novagenix Drug R&D Center, Akyurt, Ankara, Turkey Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey |
2103 | Active, not recruiting | Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions | Bioequivalence | Drug: AVICOD 200 MG Film Tablet Drug: AVIGAN 200 MG Film Tablets |
Phase 1 | Pharma Plant, Novagenix Bioanalytical Drug R&D Center | INDUSTRY | 30 | Male | 18 Years ~ 55 Years | Novagenix Drug R&D Center, Akyurt, Ankara, Turkey |